Psoriasis Clinical Trial

Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis

Summary

Patients with moderate to severe plaque psoriasis will be treated with Otezla BID. At week 8, non responders will be discontinued, partial responders will be given add-on Enstilar QD for 4 weeks and PASI 75 responders will remain on Otezla monotherapy through week 16.

View Full Description

Full Description

50 adult patients with moderate to severe plaque psoriasis will be given OTEZLA® for 16 weeks with add-on Enstilar.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Male or female adult ≥ 18 years of age;
Diagnosis of chronic plaque-type psoriasis

Moderate to severe plaque type psoriasis as defined at baseline by:

PGA score of 3 or greater
BSA affected by plaque-type psoriasis of 10% or greater
PASI ≥ 12
Able and willing to give written informed consent prior to performance of any study-related procedures
Must be in general good health (except for disease under study) as judged by the Investigator, based on medical history, physical examination, clinical laboratories, and urinalysis. (NOTE: The definition of good health means a subject does not have uncontrolled significant co-morbid conditions).

Exclusion Criteria:

Other than psoriasis, any clinically significant (as determined by the investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is uncontrolled.
Forms of psoriasis other than chronic plaque-type (e.g., Pustular erythrodermic and/or guttate psoriasis) or drug induced psoriasis
Subjects who previously used any biologic agent for psoriasis.
Use of oral systemic medications for the treatment of psoriasis within 4 weeks (includes, but not limited to, oral corticosteroids, methotrexate, acitretin and cyclosporine).
Patient used topical therapies to treat psoriasis on the hands and/or feet within 2 weeks of the Baseline Visit (includes, but not limited to, topical corticosteroids, vitamin D analogs, or retinoids).
Patient received UVB phototherapy within 2 weeks of Baseline.

Study is for people with:

Psoriasis

Phase:

Phase 4

Estimated Enrollment:

50

Study ID:

NCT03587194

Recruitment Status:

Completed

Sponsor:

Psoriasis Treatment Center of Central New Jersey

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Psoriasis Treatment Center of Central New Jersey
East Windsor New Jersey, 08520, United States

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 4

Estimated Enrollment:

50

Study ID:

NCT03587194

Recruitment Status:

Completed

Sponsor:


Psoriasis Treatment Center of Central New Jersey

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.